Finally, NRG1 fusion partners were most commonly ATP1B1 (pancreatic cancer) or CD74 (NSCLC) in FDA-approved indications, with a mix of these as well as SLC3A2 and RBPMS being commonly observed partner genes in nonapproved indications. The gene discussed is SLC3A2; the disease is pancreatic neoplasm.